Neutrophil lymphocyte ratio and clinical response after neoadjuvant chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil regiment in locally advanced breast cancer

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The neutrophil to lymphocyte ratio (NLR) has been used as systemic inflammation biomarker in breast cancer. This study analyzed relationship between the NLR level and clinical responses after neoadjuvant chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) regiment in locally advanced breast cancer (LABC) patients. Methods: A cohort study was conducted in female patients with LABC who underwent CAF’s first-line neoadjuvant chemotherapy at Dr. Soetomo General Hospital, Surabaya, Indonesia from September 2019 to December 2019. Results: Of 25 patients, 2 subjects were <35 years old (8%), 11 subjects were 36-52 years old (44%), and 12 subjects were >52 years old (48%). Three (12%) subjects were in stage IIIA, 21 (84%) subjects were in stage IIIB, and 1 (4%) subject was in stage IIIC. Mean NLR level was 2.6. NLR after chemotherapy was found low in 10 subjects (40%) and high in 15 subjects (60%). Negative clinical response after chemotherapy was found in 14 subjects (56%), and positive response was found in 11 subjects (44%). There was significant correlation between NLR and clinical response (p = 0.049, OR = 6.417). Conclusion: There was relationship between NLR and clinical response in LABC patients during three cycles of neoadjuvant chemotherapy with CAF regiment. The LABC patients with a high NLR had six times worse clinical response than the ones with low NLR.

Original languageEnglish
Pages (from-to)2473-2478
Number of pages6
JournalEurAsian Journal of BioSciences
Volume14
Issue number1
Publication statusPublished - 1 Jan 2020

Keywords

  • Locally advanced breast cancer (LABC)
  • Neoadjuvant chemotheraphy CAF
  • Neutrophyl lymphocyte ratio

Fingerprint

Dive into the research topics of 'Neutrophil lymphocyte ratio and clinical response after neoadjuvant chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil regiment in locally advanced breast cancer'. Together they form a unique fingerprint.

Cite this